Alzheon, Inc. announced that scientific poster #P59, APOE4/4 Subjects with Early Alzheimer’s Disease Show Accelerated Loss of Cortical Thickness and Cognitive Decline Compared to APOE3/3 Subjects, is scheduled for presentation on December 5, 2019, at 3:30 p.m. local time in Poster Session Theme 3: Clinical Trials Imaging, at the CTAD conference in San Diego, USA. In this study, the company researchers analysed clinical and MRI imaging datasets from the AD Neuroimaging Initiative 1 (ADNI-1): late Mild Cognitive Impairment (MCI) and Mild AD groups – collectively called “Early AD” – to compare patients homozygous for the apolipoprotein e4 allele (APOE4/4) to those with APOE3/3 genotype. The rate of cortical thickness loss was shown to be significantly higher in Early AD patients with the APOE4/4 genotype. Cortical thickness loss also showed significant correlation to cognitive decline at the MCI stage. Therefore, cortical thinning could be a valuable imaging biomarker in future trials of APOE4/4 subjects who are at risk of early disease progression. The company’s lead product candidate, ALZ-801, was designed to achieve high brain levels with oral administration to fully inhibit the formation of toxic soluble amyloid oligomers, with little effect on the other forms of amyloid that may be necessary for brain health. ALZ-801 oral tablet shows a favorable long-term safety profile, with no reports of vasogenic edema, and received Fast Track designation from the U.S. Food and Drug Administration (FDA). Building upon the clinical validation from intravenous anti-amyloid antibodies aducanumab and BAN2401, which showed the therapeutic efficacy of targeting toxic beta amyloid oligomers, the company intends to launch the Phase 3 trial with ALZ-801 oral tablet in 2020.